The feasibility of plerixafor as a second-line stem cell mobilizing agent in children

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 1, 2011, Pages 65-67

  Aabideen, Kanakkande ^a   Anoop, Parameswaran ^a   Ethell, Mark E ^a   Potter, Mike N ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

AMD3100; plerixafor; Stem cell mobilization

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; METHOTREXATE; PLERIXAFOR; RITUXIMAB; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CD34 SELECTION; CHILD; DRUG MEGADOSE; FEMALE; HUMAN; LUNG METASTASIS; LYMPHADENOPATHY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEM CELL MOBILIZATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDULLOBLASTOMA; NEOPLASM STAGING; WILMS TUMOR;

EID: 78650797113     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e9e4c2     Document Type: Article

References (8)

1. Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1253-1261.
2. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non- Hodgkin's lymphoma. J Clin Oncol. 2009;27:4767-4773.
3. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720-5726.
4. Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with GCSF and plerixafor (AMD3100): An institutional experience. Bone Marrow Transplant. 2009;43:909-917.
5. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005; 106:1867-1874.
6. Toledano H, Yahel A, Cohen IJ, et al. Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSF following high dose craniospinal irradiation for medulloblastoma in a young child. Pediatr Blood Cancer. 2010;54:613-615.
7. Robertson KA, Pradhan K, Goebel S, et al. Abstract 216. Mobilization of peripheral blood CD34 stem cells in a heavily pre-treated pediatric medulloblastoma patient using AMD3100 and G-CSF. Biol Blood Marrow Transplant. 2006;12 (suppl 1): 75-76.
8. Stephen K, Montgomery K, Bateman C, et al. Abstract 457. Successful mobilisation, harvest, and transplant of stem cells following AMD3100 in 3 paediatric patients: The Australian experience. Biol Blood Marrow Transplant. 2006;12 (suppl 1):157.